{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"RP2D was to be determined based on the safety and tolerability profile of the study treatment.","groups":[{"description":"Participants received alectinib at a dose of 600 mg via capsule, orally, twice daily, continuously starting on Day 1 Cycle 1 (in 28-day cycles) until PD, death, or withdrawal for any other reasons, whichever occurred first. After PD, participants were allowed to continue treatment with alectinib as per the discretion of the treating physician.","id":"OG000","title":"Alectinib"}],"populationDescription":"The endpoint was not analyzed in this study as the RP2D was confirmed in study NP28761 (NCT01871805).","reportingStatus":"POSTED","timeFrame":"Cycle 1 (up to 28 days)","title":"Recommended Phase 2 Dose (RP2D) of Alectinib","type":"PRIMARY"}